Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Novo Nordisk's experimental weight loss pill has some concerning side effects
Ozempic maker Novo Nordisk (NVO) announced mixed results today for a phase 2 trial of an experimental weight loss pill that works differently than its already-popular weight loss drug Wegovy.
High-Flying Novo Nordisk Dips On Disappointing Data for Weight-Loss Pill
Novo Nordisk’s American depositary receipts tumbled almost 6% Friday after the drugmaker reported mixed results from a study of an experimental weight-loss pill. The pill, monlunabant, helped people lose weight in the mid-stage study,
Novo Nordisk sees mixed results for new CB1 weight-loss pill
Novo Nordisk (NVO) stock is falling Friday morning after the pharmaceutical giant shared that additional weight loss tied to higher doses of its oral drug was "limited" in its latest trial results. Morning Brief's Seana Smith and Brad Smith report on what this story means for the company.
Early trial shows success for daily weight loss pill: 3 things to know
The maker of injectable weight loss drugs including Ozempic and Wegovy is touting the results of an early-stage trial that delivered weight loss success by taking a daily pill. Novo Nordisk released data Wednesday showing that patients taking its new medication,
Novo Nordisk’s new weight-loss pill Amycretin beats Wegovy in early trial
Ozempic maker Novo Nordisk’s highly anticipated new obesity pill, Amycretin, shows the potential for much greater and faster weight loss than Wegovy in early clinical trials, according to data presented Wednesday at the European Association for the Study of Diabetes.
Novo Nordisk’s amylin pill leads to substantial weight loss in early study
Novo Nordisk reported that its new obesity pill led to substantial weight loss in an early study, boosting the company’s pipeline of next-generation candidates.
Ozempic maker has developed a pill that can cause weight loss of up to 13% in three months
The drug manufacturer has developed a pill that could bring about weight loss of as much as 13% in three months, according to results of a Phase 1 trial. The pill isn’t Ozempic—it’s called Amycretin—but like that drug it mimics the GLP-1 hormone, which suppresses people’s appetites. It also mimics amylin, which makes people feel full.
Novo Shares Fall on Safety Data for New Weight-Loss Drug
Shares of Novo Nordisk A/S fell after the Danish drugmaker reported mixed safety data on one of its next-generation weight-loss drugs.
Novo Nordisk shares drop nearly 5% on disappointing obesity pill data
Novo Nordisk's shares fell nearly 5% on Friday after results from a Phase 2a trial of the Danish drugmaker's experimental obesity pill monlunabant came in below market expectations.
Viking, Structure, Terns benefiting from disappointing Novo Nordisk weight loss data
Structure Therapeutics (NASDAQ:GPCR), and Terns Pharmaceuticals (NASDAQ:TERN), which are all developing oral pills as weight loss treatments, are trading higher Friday following disappointing results from a rival Novo Nordisk (NVO) drug.
8d
on MSN
‘Dual-action’ weight-loss pill helps people drop 13% of body weight in three months in early trials
An experimental weight-loss pill helped people drop 13% of their body weight in a three-month period. The results from early ...
4d
The Weight Loss Hacks That Claim to Work Like Ozempic
Kourtney Kardashian’s new “GLP-1 Daily” pill is the latest product to capitalize on the weight loss drug craze.
Yahoo
4d
Once-a-day weight loss pill shows promise in trial
A new
weight
loss
pill
developed by the maker of Ozempic and Wegovy helped overweight and obese people lose up to 13% ...
BioSpace
19h
Novo’s Next-Gen CB1 Drug Leads to Weight Loss in Phase II, but Neuropsychiatric Events Reported
Novo Nodrisk’s cannabinoid receptor–targeting obesity pill was picked up in the $1.1 billion acquisition of Inversago ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Novo Nordisk
Wegovy
Kourtney Kardashian
Feedback